{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T23:05:35Z","timestamp":1773183935754,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019125","name":"National Institute of Pharmaceutical Education and Research, Ahmedabad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019125","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014824","name":"Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014824","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejpb.2026.115010","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T15:57:58Z","timestamp":1770134278000},"page":"115010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A way forward for generic development of telmisartan tablets: Integrating critical material attributes and bio-predictive dissolution for target product profile"],"prefix":"10.1016","volume":"222","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-533X","authenticated-orcid":false,"given":"Megha","family":"Pillai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7238-6630","authenticated-orcid":false,"given":"Ravi P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6914-7057","authenticated-orcid":false,"given":"Pinaki","family":"Sengupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2026.115010_b0005","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1208\/s12249-018-1197-7","article-title":"Power of the dissolution test in distinguishing a change in dosage form critical quality attributes","volume":"19","author":"Gray","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2026.115010_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12249-019-1479-8","article-title":"Advancements in dissolution testing of oral and non-oral formulations","volume":"20","author":"Klein","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2026.115010_b0015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejpb.2020.08.005","article-title":"Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary","volume":"155","author":"Jamei","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115010_b0020","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s12247-021-09565-2","article-title":"Recent advances in dissolution testing and their use to improve in vitro\u2013in vivo correlations in oral drug formulations","volume":"17","author":"Ranjan","year":"2021","journal-title":"J. Pharmaceut. Innovat."},{"key":"10.1016\/j.ejpb.2026.115010_b0025","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1208\/s12248-011-9272-y","article-title":"Dissolution testing for generic drugs: An FDA perspective","volume":"13","author":"Anand","year":"2011","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2026.115010_b0030","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2026.115010_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2016.11.004","article-title":"Biopharmaceutical aspects and implications of excipient variability in drug product performance","volume":"111","author":"Zarmpi","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115010_b0040","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejpb.2020.07.014","article-title":"Biopharmaceutical implications of excipient variability on drug dissolution from immediate release products","volume":"154","author":"Zarmpi","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115010_b0045","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jps.24643","article-title":"Effect of common excipients on the oral drug absorption of biopharmaceutics classification system class 3 drugs cimetidine and acyclovir","volume":"105","author":"Vaithianathan","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115010_b0050","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejpb.2019.05.020","article-title":"Potential for pharmaceutical excipients to impact absorption: A mechanistic review for BCS Class 1 and 3 drugs","volume":"141","author":"Flanagan","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115010_b0055","first-page":"1","article-title":"A critical overview of the biological effects of excipients (Part I): impact on gastrointestinal absorption","volume":"24","author":"Martinez","year":"2022","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2026.115010_b0060","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ejps.2017.12.029","article-title":"The effect of formulation additives on in vitro dissolution-absorption profile and in vivo bioavailability of telmisartan from brand and generic formulations","volume":"114","author":"Borb\u00e1s","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115010_b0065","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejps.2014.02.010","article-title":"In vivo methods for drug absorption - Comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation\/API\/excipient characterization including food effects","volume":"57","author":"Sj\u00f6gren","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115010_b0070","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0928-0987(01)00095-1","article-title":"Modeling and comparison of dissolution profiles","volume":"13","author":"Costa","year":"2001","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115010_b0075","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1208\/s12248-015-9830-9","article-title":"Dissolution similarity requirements: how similar or dissimilar are the global regulatory expectations?","volume":"18","author":"Diaz","year":"2016","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2026.115010_b0080","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejps.2014.10.002","article-title":"In vitro dissolution similarity factor (f2) and in vivo bioequivalence criteria, how and when do they match? Using a BCS class II drug as a simulation example","volume":"66","author":"Xie","year":"2015","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejpb.2026.115010_b0085","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.xphs.2021.10.017","article-title":"Physiologically based biopharmaceutics modeling to demonstrate virtual bioequivalence and bioequivalence safe-space for ribociclib which has permeation rate-controlled absorption","volume":"111","author":"Laisney","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115010_b0090","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejps.2006.05.004","article-title":"Biorelevant dissolution media as a predictive tool for glyburide a class II drug","volume":"29","author":"Wei","year":"2006","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115010_b0095","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejpb.2015.10.012","article-title":"A new biorelevant dissolution method for orodispersible films","volume":"98","author":"Krampe","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115010_b0100","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.xphs.2021.08.026","article-title":"Increasing the robustness of biopharmaceutical precipitation assays \u2013 Part II: recommendations on the use of FaSSIF","volume":"111","author":"Krollik","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115010_b0105","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0378-5173(00)00581-0","article-title":"Evaluation of dissolution profiles using principal component analysis","volume":"212","author":"Adams","year":"2001","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115010_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122890","article-title":"Multivariate data analysis to evaluate commonly used compression descriptors","volume":"637","author":"Berkenkemper","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115010_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106836","article-title":"Analysis of the impact of material properties on tabletability by principal component analysis and partial least squares regression","volume":"200","author":"Mareczek","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115010_b0120","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-020-01643-x","article-title":"Understanding the oral absorption of irbesartan using biorelevant dissolution testing and PBPK modeling","volume":"21","author":"Kaur","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2026.115010_b0125","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1021\/js980434g","article-title":"Selection of solid dosage form composition through drug-excipient compatibility testing","volume":"88","author":"Serajuddin","year":"1999","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115010_b0130","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-023-02573-0","article-title":"Drug-excipient compatibility study through a novel vial-in-vial experimental setup: a benchmark study","volume":"24","author":"Jain","year":"2023","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2026.115010_b0135","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40005-017-0310-3","article-title":"Design of supersaturable formulation of telmisartan with pH modifier: in vitro study on dissolution and precipitation","volume":"47","author":"Yamashita","year":"2017","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.ejpb.2026.115010_b0140","doi-asserted-by":"crossref","first-page":"32466","DOI":"10.1021\/acsomega.0c04588","article-title":"Lyophilized amorphous dispersion of telmisartan in a combined carrier-Alkalizer system: formulation development and in vivo study","volume":"5","author":"Chatterjee","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejpb.2026.115010_b0145","unstructured":"Center for drug evaluation and research application number: NDA 20850. clinical pharmacology and biopharmaceutics review(S), (n.d.)."},{"key":"10.1016\/j.ejpb.2026.115010_b0150","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1021\/mp100149j","article-title":"Physiological parameters for oral delivery and in vitro testing","volume":"7","author":"Mudie","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2026.115010_b0155","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1023\/A:1015827908309","article-title":"Upper gastrointestinal (GI) pH in young, healthy men and women","volume":"7","author":"Dressman","year":"1990","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2026.115010_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106864","article-title":"New mathematical model from dynamic dissolution rate tests","volume":"201","author":"Ruiz-Picazo","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115010_b0165","doi-asserted-by":"crossref","first-page":"15380","DOI":"10.1021\/acsomega.8b02144","article-title":"Enhanced solubility of telmisartan phthalic acid cocrystals within the pH range of a systemic absorption site","volume":"3","author":"Kundu","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejpb.2026.115010_b0170","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s12272-011-0315-9","article-title":"Comparative study of telmisartan tablets prepared via the wet granulation method and PritorTM prepared using the spray-drying method","volume":"34","author":"Park","year":"2011","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.ejpb.2026.115010_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121415","article-title":"Level A IVIVC for immediate release tablets confirms in vivo predictive dissolution testing for ibuprofen","volume":"614","author":"C\u00e1mara-Martinez","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115010_b0180","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1098\/rspb.2004.2886","article-title":"Gastric flow and mixing studied using computer simulation","volume":"271","author":"Pal","year":"2004","journal-title":"Proc. Biol. Sci."},{"key":"10.1016\/j.ejpb.2026.115010_b0185","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1021\/acs.molpharmaceut.3c01203","article-title":"Comparative evaluation of dissolution performance in a USP 2 setup and alternative stirrers and vessel designs: a systematic computational investigation","volume":"21","author":"Salehi","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2026.115010_b0190","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijpharm.2004.08.003","article-title":"Hydrodynamics-induced variability in the USP apparatus II dissolution test","volume":"292","author":"Baxter","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115010_b0195","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/jps.22343","article-title":"MRI Studies of the Hydrodynamics in a USP 4 Dissolution Testing Cell","volume":"100","author":"Shiko","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115010_b0200","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijpharm.2009.04.012","article-title":"Mathematical modeling of the fluid dynamics in the flow-through cell","volume":"376","author":"Kakhi","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115010_b0205","article-title":"Effect of pH modifiers on the solubility, dissolution rate, and stability of telmisartan solid dispersions produced by hot-melt extrusion technology","volume":"65","author":"Almotairy","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2026.115010_b0210","unstructured":"Boehringer ingelheim pharmaceuticals, highlights of prescribing information, n.d. https:\/\/www.fda.gov\/drugsatfda."},{"key":"10.1016\/j.ejpb.2026.115010_b0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cmr.a.10080","article-title":"NMR spectroscopy in the study of carbohydrates: characterizing the structural complexity","volume":"19A","author":"Bubb","year":"2003","journal-title":"Concepts Magn. Reson. Part A"},{"key":"10.1016\/j.ejpb.2026.115010_b0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-33104-8","article-title":"NMR spectroscopy enables simultaneous quantification of carbohydrates for diagnosis of intestinal and gastric permeability","volume":"8","author":"Stryeck","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpb.2026.115010_b0225","unstructured":"Simple 1H NMR spectroscopic method for assay of salts of the contrast agent diatrizoate in commercial solutions - PubMed, (n.d.). https:\/\/pubmed.ncbi.nlm.nih.gov\/8757438\/ (accessed April 16, 2025)."},{"key":"10.1016\/j.ejpb.2026.115010_b0230","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1039\/C3OB42338G","article-title":"Disodium cromoglycate: exploiting its properties as a NMR weak-aligning medium for small organic molecules","volume":"12","author":"Troche-Pesqueira","year":"2014","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejpb.2026.115010_b0235","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/jps.20330","article-title":"Single crystal and powder diffraction characterization of three polymorphic forms of acitretin","volume":"94","author":"Malpezzi","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115010_b0240","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/1520-6017(200011)89:11<1465::AID-JPS9>3.0.CO;2-C","article-title":"Structural characterization of three crystalline modifications of telmisartan by single crystal and high\u2010resolution X\u2010ray powder diffraction","volume":"89","author":"Dinnebier","year":"2000","journal-title":"J. Pharm. Sci."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126000317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126000317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T03:48:11Z","timestamp":1773114491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641126000317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":48,"alternative-id":["S0939641126000317"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115010","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A way forward for generic development of telmisartan tablets: Integrating critical material attributes and bio-predictive dissolution for target product profile","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115010"}}